Skip to main content
Clinical Trials/NCT06647537
NCT06647537Not yet recruitingNot Applicable

Frequency of Neonatal Hyperglycemia at Assuit University Children Hospital

Assiut University0 sites20 target enrollmentStarted: November 1, 2024Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
20
Primary Endpoint
1-Detection of prevalence of neonatal hyperglycemia by estimating RBG level in serum 2-Assessment of risk factors, clinical characteristics and possible complications of neonatal hyperglycemia.

Study Overview

Brief Summary

Detection of prevalence of neonatal hyperglycemia and assessment of risk factors, clinical characteristics and possible complications of neonatal hyperglycemia.

Detailed Description

Hyperglycemia has become an important risk factor for mortality and morbidity in the neonatal period, especially with increased survival rates of very low birth weight neonates.

Neonatal hyperglycemia is usually defined as serum glucose greater than 150 mg/dl (8.3 mmol/L) or whole blood glucose greater than 125 mg/dl (6.9 mmol/L) irrespective of gestational or postmenstrual age. Usually, the safe target for a neonate's serum glucose level is 70 to 150 mg/dl. The cut off for safe target is based on the renal glucose threshold of preterm neonates.

Hyperglycemia is more common in preterm infants than term infants as it occurs in one-third of preterm and small gestational age (SGA) infants and is generally noted during the first week of life. Usually, the acute hyperglycemia resolves over two to three days in most neonates but can last up to ten days. Hyperglycemia is less common than hypoglycemia among neonates but is associated with increased mortality and morbidity among neonates. Neonatal hyperglycemia is inversely related to birth weight and gestational age.

Glucose is an essential source of energy for the fetus and neonate. The brain growth of the fetus exclusively depends upon glucose. In the early postnatal period, glucose homeostasis occurs via glycogenolysis and gluconeogenesis. The critical regulatory mechanisms of glucose homeostasis are sluggish in the initial days, particularly among preterm neonates. The mechanisms of neonatal hyperglycemia are multifactorial. The risk of hyperglycemia increases with the severity of the accompanying illness. The most common cause is high exogenous glucose infusion rates (GIR) in preterm infants who are already at risk for hyperglycemia due to the following reasons,

  • decreased ability to suppress endogenous glucose production,
  • decreased insulin response to glucose, and
  • limited glycogen and fat stores. Hyperglycemia in the neonatal period develops as a result of other multiple risk factors including.

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Prospective

Eligibility Criteria

Ages
— to 28 Days (Child)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •all neonates from day 0 to 28 days old admitted in NICU.

Exclusion Criteria

  • •> 28 days old

Outcomes

Primary Outcomes

1-Detection of prevalence of neonatal hyperglycemia by estimating RBG level in serum 2-Assessment of risk factors, clinical characteristics and possible complications of neonatal hyperglycemia.

Time Frame: 1-11-2024

assesment how many children diagnosed with neonatal hyperglycemia . what are risk factors those cause this problem . what are the manifestationsof neonatal hyperglycemia and possible complications of neonatal hyperglycemia

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Hend Rashad abdeltawab

doctor

Assiut University

Similar Trials